Toxicity related to autologous PBSC infusion is well known and traditionally attributed to the presence of DMSO as cryoprotectant. But despite DMSO depletion, adverse events continue appearing. We have conducted a retrospective study to determine the incidence of adverse events related to the PBSC infusion in a large series of 144 patients. Adverse effects were observed in 67.36% of patients, although most of them were of grade 1 or 2. The adverse events most frequently reported were allergic reactions, followed by general, gastrointestinal and respiratory symptoms. In the univariate analysis, age (P ¼ 0.01), the volume infused (P ¼ 0.005), the amount of DMSO (P ¼ 0.008), the total nucleated cells (P ¼ 0.002), the total number of granulocytes (P ¼ 0.000001) and clumping (P ¼ 0.000001) were associated with the occurrence of adverse events. In the multivariate analysis, two protective factors, age (P ¼ 0.05) and sex (P ¼ 0.004), and two risk factors, the number of granulocytes, with a relative risk of 1.18 (95% confidence interval, 1.06-1.31) (P ¼ 0.002), and clumping, with an relative risk of 1.94 (95% confidence interval, 1.15-3.29) (P ¼ 0.013), were identified. The best cutoff point for the prediction of the occurrence of adverse events, with a sensitivity of 47% and specificity of 89%, was 6.065 Â 10 9 granulocytes.
Introduction
High-dose chemotherapy followed by autologous peripheral blood stem cell (PBSC) transplantation is used routinely for many haematological malignancies. PBSCs are often mobilized from the bone marrow with cytokines such as recombinant G-CSF (rhuG-CSF) and then cryopreserved. This process requires the addition of cryopreservatives such as DMSO to prevent cell lysis during freezing. 1 The occurrence of adverse events during the infusion of previously cryopreserved autologous PBSC is well known. [2] [3] [4] These events have traditionally been attributed to the presence of DMSO in the thawed cell suspension. The infusion of DMSO gives rise to dosedependent gastrointestinal, cardiovascular and neurological toxicity. [1] [2] [3] Non-allergic hypotension may result from an infusion of DMSO, probably related to histamineinduced vasodilatation if the recipient is not adequately premedicated with antihistamine drugs. Skin flushing, dyspnoea, abdominal cramps, nausea and diarrhoea can also be attributed to DMSO-induced histamine release. DMSO does not need to be removed before infusion because these adverse events resolve over a few hours, can be treated symptomatically and the toxicity is not severe. Several studies have assessed whether the depletion of DMSO prior to autografting affects the safety and efficacy. Some studies reported a reduction in side effects when the cryopreserved cells were infused after washing in normal saline. 5 But despite DMSO depletion, these side effects still continue to appear 6 and the role of DMSO in their pathogenesis is questioned.
This study was performed to determine the incidence and severity of adverse events related to the PBSC infusion and to identify the risk factors associated with these reactions in a large cohort of patients receiving autografts for haematological malignancies in our institution.
Methods
The criterion for enrolment in the study was the diagnosis of a haematological malignancy suitable for high-dose chemotherapy followed by autologous stem cell rescue. To obtain a homogenous cohort, we included only patients with lymphoid malignancies, as those with myeloid malignancies do not usually receive autografts in our centre. Mobilization was performed with rhuG-CSF filgrastim (Neupogen, Amgen Europe B.V., Breda, The Netherlands) at a dose of 10-20 mg/kg/day subcutaneously for 5 days in accordance with our scoring, or in combination with chemotherapy. PBSCs were collected using a COBE Spectra (Gambro BCT Inc., Lakewood, CO, USA) as described previously. 6 The collection target for transplantation was a minimum of 2 Â 10 6 CD34 þ cells/ kg. For cryopreservation, the apheresis product was diluted with an equal volume of cryoprotectant solution containing 5-10% DMSO and autologous plasma from the excess previously removed. The cells were frozen in methanol at À80 1C, as described previously, 7 and then stored in the vapour phase of liquid nitrogen. Cryopreserved cells were infused at least 48 h after the administration of the last dose of chemotherapy. Two hours before the infusion, all patients received premedication with steroids (100 mg hydrocortisone), antihistamines (5 mg dexchlorpheniramine) and anti-emetic drugs (1 mg clonazepam). On the day of infusion, the cells were thawed in a water bath at 37 1C until complete dissolution of ice crystals and were infused with no further manipulation through a blood administration set with an in-line 170-mm filter via a central venous catheter. The toxicity of the infusion was evaluated using the vital signs and a report sheet filled in by the medical team responsible for the patient.
Statistical analysis
The data were analysed in the Biostatistics Department using the SPSS 9.0 software package (SPSS Inc.). The qualitative data are expressed as absolute frequencies and percentages and the quantitative data as described using the mean, median and s.d. (maximum, minimum), depending on the distribution of the data. Student's t-test for unpaired data and the Mann-Whitney U-test were used to compare quantitative data between the two groups and the w 2 test or Fisher's exact test for qualitative data. Depending on the distribution of the variables, the Pearson's or Spearman's coefficients of correlation were calculated as the bivariate coefficient of correlation. The receiver operating characteristic (ROC) curve was used to validate the model result from the multivariate analysis. The area under the ROC curve was calculated to determine the maximum sensitivity and specificity of the number of granulocytes as a diagnostic test for the onset of adverse effects attributable to the infusion. All the statistical tests have been considered to be two-sided and significance was taken as a P-value less than 0.05.
Results
From January 1998 to October 2006, 144 patients with lymphoid malignancies were treated in our Bone Marrow Transplant Unit and were eligible for enrolment in this study. The patient characteristics are shown in Table 1 . There were 69 men and 75 women, with a median age of 42 years. It should be stated that paediatric patients were included in the study population. The majority of the patients (61.1%) had a diagnosis of non-Hodgkin's lymphoma. With regard to the treatments received previously, most of our patients received the autograft after one or two previous courses of chemotherapy and were not heavily pretreated (40.3 and 32.6%, respectively). According to our mobilization score, nearly half of the patients received rhuG-CSF at a dose of 10 mg/kg/day, and only 23% were mobilized with double dose of filgrastim (20 mg/ kg/day). Only 30% of patients were mobilized with a combination of rhuG-CSF plus chemotherapy. Mobilization with rhuG-CSF alone was effective in more than twothirds of the cohort.
The graft characteristics are shown in Table 2 . The median volume infused was 696 ml, with a median volume of DMSO of 56.2 ml. The median numbers of total nucleated cells and CD34 þ cells were 14.59 Â 10 8 and 3.5 Â 10 6 cells/kg, respectively. The median total number of granulocytes infused was 3.87 Â 10 9 . Clumping was evaluated using a qualitative scale. No clumping of the product was observed in 45%; when clumping occurred, it was of grade 1 or 2. Viability was tested with Trypan blue staining, with a median value of 97%.
During the autologous PBSC infusion, 97 patients (67.36%) developed adverse events (Figure 1 ). The majority were grade 1 (59%) according to the toxicity scale of the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). Only one grade 3 toxicity was observed and no grade 4. Eighty-one of the 97 patients who developed adverse events presented between one and three events during the infusion, and only a small proportion suffered more than three (Figure 2) . Specifically, the adverse events most commonly reported were allergic reactions (n ¼ 63) such as rash, facial flushing and bronchospasm. Other adverse events with a high incidence reported by the Figure 3 ). In the univariate analysis, the factors showing a statistically significant association with the onset of adverse events were age, total volume infused, amount of DMSO, total nucleated cells/kg, total number of granulocytes and clumping. With respect to sex, female patients suffered more adverse events than the male patients (78.7 vs 53.6%, P ¼ 0.002). When examining the underlying disease, patients with Hodgkin's lymphoma presented more adverse events (81.1%) compared to those with non-Hodgkin's lymphoma (60.2%) or multiple myeloma (68.4%), although the difference did not reach statistical significance.
In the multivariate analysis, we have identified four factors that predict the occurrence of adverse events during the infusion of the autografts: age, gender, total number of granulocytes and clumping (Table 3) . Older patients and men had a lower incidence of adverse events in comparison with younger patients and women. Among the characteristics of the graft, the number of granulocytes and clumping were found to be risk factors, with relative risks of 1.18 (95% confidence interval, 1.06-1.31) and 1.94 (95% Adverse events during the infusion of autologous PBSCconfidence interval, 1.15-3.29), respectively. The ROC curve, shown in Figure 4 , was used to validate the scores for these four factors; the area under the curve was 0.826, with a lower boundary of 0.751 and an upper boundary of 0.9 (P ¼ 0.00001).
Within the adverse event group, there was a strong correlation between the number of granulocytes and the number of adverse events (n ¼ 37 with one event, median 9 Â 10 9 granulocytes; n ¼ 27 with two events, median 10 Â 10 9 granulocytes; n ¼ 17 with three events, median 12 Â 10 9 granulocytes; n ¼ 12 with four events, median 13 Â 10 9 granulocytes; and n ¼ 3 with five events, median 22 Â 10 9 granulocytes). However, there was no significant correlation between the number of granulocytes and the degree of severity of the toxicity. Using the ROC curve, we have determined that 6.065 Â 10 9 granulocytes was the best cutoff to predict the occurrence of adverse events, with a sensitivity of 47% and a specificity of 89%.
Discussion
The aim of this study has been to identify the factors associated with the onset of adverse events during the infusion of cryopreserved autologous PBSC. Traditionally, these events have been attributed to the presence of the cryopreservative DMSO in the autografts, but this is now being questioned. Several studies have reported a lower incidence of adverse events when DMSO is depleted from the autograft prior to the infusion. [8] [9] [10] However, the laboratory procedure is time consuming and side effects continue to occur despite removal of DMSO. 10 In a large series of 460 patients in which DMSO was removed prior to infusion, adverse events were still reported despite an adequate histamine blockade, suggesting the presence of granulocyte contamination as the cause of these adverse reactions. 11 In other studies, the infusion of large quantities of cryopreserved granulocytes is postulated to be the cause of severe neurological symptoms 2 and rigors; 4 however, there are no studies that have attempted to identify the correlation between the number of granulocytes and the incidence of adverse events during the infusion to our knowledge.
In our survey, the group of patients developing adverse events received a higher volume of DMSO compared to the other group, although this difference was detected only in the univariate analysis and not in the multivariate analysis. Four factors have been identified as associated with the occurrence of adverse events during the infusion of the autografts: two intrinsic factors related to the patient, age and sex, and two extrinsic factors, the number of granulocytes and clumping. Age and sex were protective factors in our analysis. Older patients and males had fewer adverse events during the infusion of autologous PBSC. Our hypothesis for these findings involves the relationship between the body surface area and volume of the patients. As is well recognized, children and women have a smaller body surface area than adults and men, and therefore receive a higher relative final volume. The other two factors implicated in the occurrence of adverse events, number of granulocytes and clumping, were risk factors. The aetiology of the formation of fibrin clots in cryopreserved stem cell bags during the thawing procedure is still unknown and no single cause has been found. Activated monocytes, disintegrated granulocytes, a high cell concentration and the lack of anticoagulant citrate-dextrose-adenine (ACD-A) as anticoagulant at the time of collection have been postulated to be associated with clumping. 12 Activated monocytes have procoagulant activity by virtue of their secretion of tissue factor. This, plus the presence of free DNA from poorly cryopreserved cells, such as granulocytes, initiates the coagulation cascade with the diluted plasma present in the cryocyte bags. This would explain the strong correlation between the number of granulocytes and clumping and the occurrence of adverse events during the infusion. There are no differences in the apheresis procedures between our centre and the results from other studies published previously. The freezing method with methanol may differ from other studies, but we do not find this difference to be a single cause to explain our results.
The determination of the best cutoff in the number of granulocytes may predict the risk of developing of adverse events and may identify the group of patients at higher risk, permitting closer clinical observation. These patients would benefit from special care. In our experience, when the number of granulocytes is above the cutoff of 6.065 Â 10 9 or when clumping is present in the cryocyte bags, the infusion filter is replaced after the infusion of each bag and the medication given prior to the infusion to prevent adverse effects is repeated at a 2-hourly interval.
In conclusion, adverse events during the infusion of previously cryopreserved autologous PBSC are very common, but the toxicity is usually minor and self-limiting; although DMSO depletion by post-thaw washing is a feasible technique, with no influence on haematological recovery, it does not appear to be the only technique necessary to reduce the incidence of side effects. The need for a high-quality apheresis product to reduce granulocyte contamination must be stressed.
